CD8A and pancreatic ductal adenocarcinoma: Consistent with this, Azad et al. [33] showed in pancreatic ductal adenocarcinoma models that RT plus gemcitabine upregulated PD-L1 in a JAK/STAT1-dependent manner and that high but not low RT doses synergized with PD-L1 blockade to improve tumor control and augment CD8+ T cell infiltration.